Article Text

PDF
Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma
  1. A Miki,
  2. Y Oshima,
  3. Y Otori,
  4. M Kamei,
  5. Y Tano
  1. Department of Ophthalmology, Osaka University Medical School, Suita, Osaka, Japan
  1. Dr A Miki, Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E-7, Suita, Osaka 565-0871, Japan; amiki{at}ophthal.med.osaka-u.ac.jp

Statistics from Altmetric.com

Neovascular glaucoma (NVG) is a severe form of glaucoma usually associated with ischaemic retinal diseases.1 When NVG progresses with extensive retinal ischaemia, not only trabeculectomy or aqueous drainage implants alone but aggressive surgery with multiple procedures (par plana vitrectomy (PPV), endolaser photocoagulation, and simultaneous trabeculectomy) should be considered.24 However, surgical outcomes in patients with NVG are disappointing.24 Intraoperative bleeding and postoperative inflammation are major obstacles to obtaining longitudinal surgical success.

Bevacizumab (Avastin, Genentech, San Francisco) is a humanised monoclonal antibody against all vascular endothelial growth factor (VEGF) isoforms.5 Bevacizumab, a potent drug that causes rapid regression of iris and retinal neovascularisation, is a powerful adjunct for preventing intraoperative haemorrhage in proliferative diabetic retinopathy.5 6 We report that bevacizumab also can prevent unexpected …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.